🇺🇸 FDA
Patent

US 8709430

Cancer treatment kits comprising therapeutic antibody conjugates that bind to aminophospholipids

granted A61KA61K39/395A61K47/6835

Quick answer

US patent 8709430 (Cancer treatment kits comprising therapeutic antibody conjugates that bind to aminophospholipids) held by The Board of Regents of the University of Texas System expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K39/395, A61K47/6835, A61K47/6849, A61K49/04